🇺🇸 FDA
Patent

US 9517243

Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity

granted A61KA61K2039/585A61K31/7004

Quick answer

US patent 9517243 (Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/585, A61K31/7004, A61K31/7032, A61K38/2013